No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACIU240719C5000
- 0.10
- -0.20-66.67%
15min DelayClose Jul 16 15:58 ET
0.10High0.10Low
0.10Open0.30Pre Close1 Volume91 Open Interest5.00Strike Price10.00Turnover304.63%IV31.44%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1997Delta0.2770Gamma38.80Leverage Ratio-0.0525Theta0.0000Rho7.75Eff Leverage0.0009Vega
Intraday
- 5D
- Daily
News
AC Immune Showcasing Its Novel Morphomer-Antibody Drug Conjugate (MorADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
PDF VersionAC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024Three oral presentations at the Alzheimer's
AC Immune | 6-K: Report of foreign private issuer (related to financial reporting)
AC Immune SA (NASDAQ:ACIU) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
AC Immune SA (NASDAQ:ACIU) shareholders would be excited to see that the share price has had a great month, posting a 34% gain and recovering from prior weakness. The annual gain comes to 113% foll
Here's Why Shareholders May Want To Be Cautious With Increasing AC Immune SA's (NASDAQ:ACIU) CEO Pay Packet
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 250 points on Friday.Shares of RH (NYSE:RH) fell sharply in today's pre-market trading after the company reported mixed
BTIG Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $8
BTIG analyst Thomas Shrader maintains $AC Immune(ACIU.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 37.8% and a total avera
Comments
$AC Immune(ACIU.US$
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune SA (NASDAQ: ACIU) will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, showcasing its precision medicine pipeline for neurodegenerative diseases. The presentations will focus on:
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune SA (NASDAQ: ACIU) will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, showcasing its precision medicine pipeline for neurodegenerative diseases. The presentations will focus on:
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an...
ACI-24.060 represents a cutting-edge approach in the battle against Alzheimer's disease.
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising ...
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising ...
Read more